EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment

Marta Budzińska, Agnieszka Malcher iD, Agnieszka Zimna iD, Maciej Kurpisz iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252211869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Marta Budzińska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics Polish Academy of Sciences, 60-479 Poznan, Poland. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Induced Pluripotent Stem Cells, Genetic Therapy, Dystrophin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by disruptions in the dystrophin gene. This study aims to investigate potential a therapeutic approach using genetically modified human iPS-derived mesoangioblast-like cells (HIDEMs) in mdx mouse model. This study utilizes patient-specific myoblasts reprogrammed to human induced pluripotent stem cells (iPSCs) and then differentiated into HIDEMs. Lentiviral vectors carrying microdystrophin sequences have been employed to deliver the genetic construct to express a shortened, functional dystrophin protein in HIDEMs. The study indicated significant changes within redox potential between healthy and pathological HIDEM cells derived from DMD patients studied by catalase and superoxide dismutase activities. Microdystrophin expressing HIDEMs also improved expression of genes involved in STARS (striated muscle activator of Rho signaling) pathway albeit in selective DMD patients (with mild phenotype). Although in vivo observations did not bring progress in the mobility of mdx mice with HIDEMs, microdystrophin interventions this may argue against “treadmill test” as suitable for assessment of mdx mice recovery. Low-level signaling of the Rho pathway and inflammation-related factors in DMD myogenic cells can also contribute to the lack of success in a functional study. Overall, this research contributes to the understanding of DMD pathogenesis and provides insights into potential novel therapeutic strategy, highlighting the importance of personalized gene therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneInduced Pluripotent Stem CellsGenetic TherapyDystrophinMice, Inbred mdxHumansAnimalsMiceCell DifferentiationDisease Models, AnimalGenetic VectorsMale

Stichwörter der Autor:innen

Duchenne Muscular Dystrophygene therapymdx micemicrodystrophinmuscular dystrophy

Substanzen

Dystrophin

Autor:innen und Institutionen

  • Institute of Human Genetics Polish Academy of Sciences, 60-479 Poznan, Poland.

ORCID-Profile: Agnieszka Malcher, Agnieszka Zimna, Maciej Kurpisz

Förderung

  • National Science Centre

Zitieren

APA

Budzińska, M., Malcher, A., Zimna, A., & Kurpisz, M. (2024). In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252211869

Vancouver

Budzińska M, Malcher A, Zimna A, Kurpisz M. In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252211869

BibTeX
@article{Budziska2024,
  author = {Budzińska, Marta and Malcher, Agnieszka and Zimna, Agnieszka and Kurpisz, Maciej},
  title = {In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252211869}
}
Kostenlos starten →